Screen Shot 2020 08 02 at 19.58.38 420x300

Immuntherapy for Prostate Cancer with Gc Protein-Derived Macrophage Activating Factor

16 nonanemic prostate cancer patients received weekly administration of 100 ng of GcMAF. After 14 to 25 weekly administrations of GcMAF (100 ng/week), all 16 patients had levels equivalent to those of healthy control values, indicating that these patients are tumor-free. No recurrence occurred for 7 years.

Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto: GcMAF, Translational Oncologie: Vol 1, No 2: 65-72 (2008a)

Immunotherapy of metastatic breast cancer patients with vitamin D-binding protein-derived macrophage activating factor (GcMAF)

Efficacy of GcMAF for treatment of metastatic breast cancer was investigated with 16 nonanemic patients who received weekly administration of GcMAF (100 ng). After about 16-22 administrations (approximately 3.5-5 months) of GcMAF, these patients had insignificantly low serum enzyme levels indicating eradication of the tumors. This therapeutic procedure resulted in no recurrence for more than 4 years.

Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto, Naofumi Ushijima: International Journal of Cancer 122: 461-467 (2008b)

Immunotherapy of metastatic colorectal cancer with vitamin D-binding protein-derived macrophage-activating factor, GcMAF

After 32–50 weekly administrations of 100 ng GcMAF, all colorectal cancer patients exhibited healthy control levels of the serum Nagalase activity, indicating eradication of metastatic tumor cells. During 7 years after the completion of GcMAF therapy, their serum Nagalase activity did not increase, indicating no recurrence of cancer, which was also supported by the annual CT scans of these patients.

Nobuto Yamamoto, Hirofumi Suyama, Nobuyuki Yamamoto, Naofumi Ushijima:

Effects of vitamin D-binding protein-derived macrophage-activating factor on human breast cancer cells.

On the effects of GcMAF in human breast cancer cells in vitro. GcMAF reverts the neoplastic phenotype; cancer cells become normal and are deprived of their metastatic potential.

Pacini S, Punzi T, Morucci G, Gulisano M, Ruggiero M. Anticancer Res. 2012 Jan;32(1):45-52.

A novel role for a major component of the vitamin D axis: vitamin D binding protein-derived macrophage activating factor induces human breast cancer cell apoptosis through stimulation of macrophages.

GcMAF activates macrophages that attack and destroy human breast cancer cells. The molecular assembly and mode of action of GcMAF are elucidated. For the first time an interconnection with the vitamin D receptor (VDR) signalling is presented.

Thyer L, Ward E, Smith R, Fiore MG, Magherini S, Branca JJ, Morucci G, Gulisano M, Ruggiero M, Pacini S.Nutrients. 2013 Jul 8;5(7):2577-89. doi: 10.3390/nu5072577.

Gc protein-derived macrophage-activating factor decreases α-N-acetylgalactosaminidase levels in advanced cancer patients.

On the therapeutic effects of GcMAF in 20 patients with advanced cancer defined as incurable. Clinical cases of breast, prostate, bladder, ovarian, colon, tongue, larynx, head and neck carcinomas, lymphomas and oligodedroglioma

Thyer L, Ward E, Smith R, Branca JJ, Morucci G, Gulisano M, Noakes D, Eslinger R, Pacini S. OncoImmunology 2013; 2:e25769; http://dx.doi.org/10.4161/onci.25769.

Multifaceted immunotherapeutic effects of vitamin D-binding protein-derived macrophage activating factor (GcMAF) on human breast cancer and neuroblastoma cells.

On the multifaceted effects of GcMAF in human breast cancer cells and human neuroblastoma (a brain tumour) cells. Here it is demonstrated that when GcMAF is prepared according to its molecular configuration, it is 100 fold more effective than “regular” GcMAF in destroying human cancer cells.

Ruggiero M, Pacini S, Morucci G, Branca J, Ward E, Smith RJ, Thyer L and Gulisano M (2013). Front. Immunol. Conference Abstract: 15th International Congress of Immunology (ICI). doi: 10.3389/conf.fimmu.2013.02.00221.

Effects of vitamin D binding protein-derived macrophage activating factor on human neuroblastoma cells and predicted molecular interaction with the vitamin D receptor.

These results are consistent with the hypothesis that the known anticancer efficacy of DBP-MAF can be ascribed to different biological properties of the molecule that include inhibition of tumour-induced angiogenesis and direct inhibition of cancer cell proliferation, migration and metastatic potential.

M. Ruggiero, M.G. Fiore, S. Magherini, G. Morucci, J.J.V. Branca, M. Gulisano, L. Thyer, S. Pacini. Abstr.

Alpha‐N‐acetylgalactosaminidase levels in cancer patients are affected by Vitamin D binding protein‐derived macrophage activating factor.

GcMAF has a significant therapeutic effect in 20 patients with advanced cancer. These results are presented at the 67th National Congress of the Italian Society of Anatomy and Histology.

Gulisano M, Pacini S, Thyer L, Morucci G, Branca JJV, Smith R, Wards E and Noakes D. (P85). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S104.

Other potential therapeutic effects of GcMAF

Effects of vitamin D3 and paricalcitol on immature cardiomyocytes: a novel role for vitamin d analogs in the prevention of cardiovascular diseases.

GcMAF increases energy production at the mitochondrial level. These results explain the reported increase of energy observed by patients treated with GcMAF for different diseases.

Pacini S, Morucci G, Branca JJ, Aterini S, Amato M, Gulisano M, Ruggiero M.Nutrients. 2013 Jun 7;5(6):2076-92. doi: 10.3390/nu5062076.

Therapeutic effects of highly purified de-glycosylated GcMAF in the immunotherapy of patients with chronic diseases.

On the therapeutic effects of GcMAF in patients with cancer, autism, chronic fatigue syndrome, Lyme disease, multiple sclerosis, amyotrophic lateral sclerosis. This is the first report on the therapeutic effects of GcMAF in patients with these dreadful neurological diseases.

Lynda Thyer, Emma Ward, Rodney Smith, Jacopo J.V. Branca, Gabriele Morucci, Massimo Gulisano, David Noakes and Stefania Pacini. DOI : 10.3844/ajisp.2013.78.84. American Journal of Immunology. Volume 9, Issue 3

Initial Observations of elevated Alpha-n-Acetylgalactosaminidase Activity Associated with Autism and Observed Reductions from GC Protein—Macrophage Activating Factor Injections.

On the therapeutic effects of GcMAF in autism. Autism is eradicated in a significant percentage of cases. About 85% of subjects show improvement following GcMAF treatment.

James Jeffrey Bradstreet, emar Vogelaar and Lynda Thyer. Autism Insights 2012:4 31–38. doi: 10.4137/AUI.S10485.

Immuntherapy of HIV-Infected Patients with Gc Protein-Derived Macrophage Activating Factor (GcMAF)

Since latently HIV-infected cells are unstable and constantly release HIV virions, the activated macrophages rapidly intercept the released HIV virions to prevent reinfection resulting in exhaustion of infected cells. After less than 18 weekly administrations of 100 ng GcMAF for nonanemic patients, they exhibited low serum Nagalase activities equivalent to healthy controls, indicating eradication of HIV-infection, which was also confirmed by no infectious center formation by provirus inducing agent-treated patient PBMCs. No recurrence occurred and their healthy CD + cell counts were maintained for 7 years.

Nobuto Yamamoto, Naofumi Ushijima, Yoshihiko Koga: Journal of Medical Virology 81:16–26 (2009)

Vitamin D binding protein-derived macrophage activating factor stimulates proliferation and signalling in a human neuronal cell line.

The effects of GcMAF on human neurons explain its therapeutic effects in autism, chronic fatigue syndrome, multiple sclerosis and amyotrophic lateral sclerosis.

Morucci G, Fiore MG, Magherini S, Branca JJV, Gulisano M, Thyer L, Ruggiero M and Pacini S.

Treatment and Prevention of Cadmium-induced alterations on human neurons.

GcMAF has a neuro-protective effect against heavy metal-induced neuronal damage. Implications for autism and chronic fatigue syndrome treatment.

Morucci G, Branca JJV, Ruggiero M, Gulisano M and Pacini S. (P29). Italian Journal of Anatomy and Embryology (2013) 118 (Suppl. 2): S144.

Effects of GcMAF on human neurons and ME/CFS treatment.

GcMAF is able to increase the viability and the metabolism of human neurons, and, most important, to induce neurons to establish contact with each other. As it is well known in the field of neurosciences, a decreased connectivity among neuronal circuits is at the basis of most, if not all, neurological and neurodevelopmental disorders. The paper also explains why GcMAF combats pain.

http://thescipub.com/abstract/10.3844/ajisp.2013.120.129

Toxicology studies of GcMAF

Safety Pharmacology, Toxicology and Pharmacokinetic Assessment of Human Gc Globulin: Vitamin D Binding Protein

The performed pre‐clinical toxicology studies of human Gc globulin in mice, rats, guinea pigs, rabbits and Shetland ponies showed no toxic effects. In beagle dogs receiving a daily dose of 20 mg/kg Gc globulin intravenous for 14 days, clinical as well as histological immunological reactions caused by production of antibodies against human Gc globulin and immune complex formation were observed.

Future studies will hopefully show whether administration of Gc globulin to patients with severe tissue injuries such as trauma, liver failure and sepsis will be able to reduce the patient’s risk of developing hypercoagulation, shock and multiple organ failure.

Pihl, Joergensen, Santoni-Rugiu, Leifsson, Hansen, Laursen, Houen: Basic & Clinical Pharmacology & Toxicology, 2010, Vol 107, pp 853-60.

Share This Article

Shopping Cart

No items in cart

Select Currency

Go to top
GcMAF.LA Lista de Correo, Mailing List

No compartiremos su correo electrónico con un tercero.
We will not share your email with a third party.